AI-generated analysis. Always verify with the original filing.
Ultragenyx Pharmaceutical Inc. reported Q4 and FY 2025 financial results and announced a strategic restructuring plan involving a 10% workforce reduction and $50 million in charges. The company also provided 2026 revenue guidance and updated its path to profitability for 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by refere
Costs Associated with Exit or Disposal Activities. On February 12, 2026, the Company began implementation of a strategic restructuring plan to reduce expenses (
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated February 12, 2026. 104 The cover page from the Company’s Curre
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $673.00 | |
| Total Revenue | $207.00 | |
| Net Loss | $-575.00 | |
| Net Loss Per Share | $-5.83 | |
| Net Loss | $-129.00 | |
| Net Loss Per Share | $-1.29 | |
| Operating Expenses | $1.2K |